Synthesis and molecular docking study of novel COVID-19 inhibitors

In 2020, the world tried to combat the corona virus (COVID-19) pandemic. A proven treatment method specific to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is still not found. In this study, seven new antiviral compounds were designed for COVID-19 treatment. The ability of these compounds to inhibit COVID-19’s RNA processing was calculated by the molecular docking study. It has been observed that the compounds can have high binding affinities especially against NSP12 (between -9.06 and -8.00 kcal/mol). The molecular dynamics simulation of NSP12-ZG 7 complex proved the stability of interaction. The synthesis of two most active molecules was performed by one-pot reaction and characterized by FT-IR, $^1 H-NMR$, 13C-NMR, and mass spectroscopy. The compounds presented with their synthesis are inhibitory core structures against SARS-CoV-2 infection.

PDF

___

1. Zhou P , Yang X.L , Wang X G et. al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-273.
2. Muralidharan N, Sakthivel R, Velmurugan D, Gromiha M M. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular Structure and Dynamics 2021; 39 (7): 2673-2678. doi: 10.1080/07391102.2020.1752802. Epub 2020 Apr 16. PMID: 32248766.
3. Wit E de, Doremalen N V, Falzarano D, Munster V. J. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology 2016; 14 (8): 523-534.
4. Lu R, Li J et.al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020.
5. Zumla A, Chan J F, Azhar E I, Hui D S C, Yuen K Y. Coronaviruses — drug discovery and therapeutic options. Nature Reviews Drug Discovery 2016; 15: 327-347.
6. Arabi Y M, Asiri A Y, Assiri A M, Aziz Jokhdar H A, Alothman A et. al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 2020; 21 (8): 2-8.
7. Cao B, Wang Y, Wen D, Liu W, Wang J, et al. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. The New England Journal of Medicine 2020; 382 (19): 1787-1800.
8. Luo P, Liu Y, Qiu L, Liu X, Liu D et al. Tocilizumab treatment in COVID-19: A single center experience. Journal of Medical Virology 2020; 92: 814-818.
9. Elfiky A A, Anti-HCV, Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences 2020; 248: 117477.
10. Hendaus M A, Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. Journal of Biomolecular Structure & Dynamics 2020.
11. Elfiky A A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences 2020; 253: 117592-117592.
12. Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy 2020; 40(5):847-848.
13. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine. International Journal of Antimicrobial Agents 2020; 55 (4):105945-46.
14. Scuccimarri R, Sutton E, Fitzcharles M A. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. The Journal of Rheumatology 2020; 783-786.
15. Gupta M K, Vemula S, Donde R, Gouda G, Behera L, Vadde R. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. Journal of Biomolecular Structure & Dynamics 2020.
16. Khan S A, Zia K, Ashraf S, Uddin R, Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. Journal of Biomolecular Structure & Dynamics 2020.
17. Sinha S K, Shakya A, Prasad S K, Singh S, Gurav N S, Prasad R S, Gurav S S. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. Journal of Biomolecular Structure & Dynamics 2020.
18. Aanouz I, Belhassan A, El-Khatabi K, Lakhlifi T, El-Idrissi M, Bouachrine M. Moroccan Medicinal plants as inhibitors against SARSCoV-2 main protease: Computational investigations. Journal of Biomolecular Structure & Dynamics 2020.
19. Joshi R S, Jagdale S S, S. Bansode B, Shankar S S, Tellis M B, Pandya V K, Chugh A, Giri A P. Antiviral effects of probiotic metabolites on COVID-19. Journal of Biomolecular Structure & Dynamics 2020.
20. Sarma P, Shekhar N, Prajapat M, Avti P, Kaur H, et. al. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. Journal of Biomolecular Structure & Dynamics 2020.
21. Lei Z-N, Wu Z-X, Dong S et. al. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. Pharmacology & Therapeutics 2020; 216: 107672.
22. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19- outside-hospital-setting
23. https://www.fda.gov/media/137574/download 24. Lo M K, Jordan R, Arvey A. et. al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific Reports 2017.
25. Sheahan P, Sims A C, Leist S R et. al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communication 2020; 11(1): 222.
26. Chandra A, Vaishali G, Qamar I, Singh N. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. Journal of Biomolecular Structure & Dynamics 2020.
27. Jiménez-Alberto A R, Ribas-Aparicio M, Aparicio-Ozores G, Castelean-Vega J A. Virtual screening of approved drugs as potential SARSCoV-2 main protease inhibitors. Computational Biology and Chemistry 2020; 88: 107325
28. Hakmi M, Bouricha E M, Kandoussi I, El Harti J, Ibrahimi A. Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis. Bioinformation 2020; 16 (4): 301-306.
29. Li Z, Li X, Huang Y-Y, Wu Y, Liu R, et.al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbationbased virtual screening of existing drugs. Proceedings of the National Academy of Sciences 2020; 117 (44): 27381-87.
30. Shi S T, Lai M M C. Viral and cellular proteins involved in coronavirus replication. Current Topics in Microbiology and Immunology 2005; 287: 95-131.
31. Yoshimoto F K. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein Journal 2020; 39 (3):198-216.
32. Molecular Operating Envoriment (MOE) 2019,01: Chemical Computing Group ULC, 1010 Sherboorke St. West, Suite, 210, Montreal, QC, Canada, H3A 27R, 2019.
33. Marwin S. 2016. http://www.chemaxon.com
34. Berman H.M, Westbrooke J, Feng Z, Gilliland G, et.al., Nucleic Acids Research, 2000;28, 235. Protein Data Bank. Aviable from http://www. rcsb.org/pdb/.
35. Jin Z, Du X, Haihito Y et. al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020; 582: 289-293.
36. Yin W, Mao C, Luan X et. al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020; 368:1499-1504.
37. Kim Y, Maltseva N, Jedrzejczak R, Welk L, Endres M, et.al. Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with potential repurposing drug Tipiracil.10.2210/pdb6WXC/pdb
38. Halgren T A. J. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Computational Chemistry 1996; 17: 490-519.
39. Labute P. Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 2009; 75 (1): 187-205. 32. Molecular Operating Environment (MOE), 2019, 01; Chemical Computing Group ULC, 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2019.
40. Case D A, Cheatham T E, C. Simmerling L, Wang J, Duke R. E. et al. University of California, San Francisco. 2012.
41. Edelsbrunner H, Mucke E P. Three-Dimensional Alpha Shapes 1994.
42. Gerber P R, Müller K, J. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. Journal of Computer Aided Molecular Design1995; 9: 251-268.
43. Phillips J C, Braun R, Wang W, Gumbart J, Tajkhorshid E, et.al. Scalable molecular dynamics with NAMD. Journal of Computational Chemistry, 2005; 26: 1781–1802.
44. Humphrey W, Dalke A and Schulten K, VMD - Visual Molecular Dynamics. Journal of Molecular Graphics, 1996; 14: 33-38.
45. Piste B P, Didwagh S S. Novel one - pot Synthesis and Antimicrobial Activity of 6-chloro-2,4- diphenyl 3,4-dihydro-2H-1,3-benzoxazine derivatives. International Journal of ChemTech Research 2013; 5 (5): 2199-2203